In conclusion, the current study shows that trastuzumab-paclitaxel induces objective tumour responses in an important number of patients with EGFR mutation positive NSCLC that show HER2 expression after progression on an EGFR TKI. Here, EGFR is linked to non-small cell lung carcinoma.